Egholm Michael 4

What Happened
Michael Egholm, President & CEO and a director of Standard BioTools (LAB), received equity awards and completed a conversion/exercise of derivative awards. On 2026-03-20 he was granted 1,042,373 shares (RSUs) and 2,345,340 derivative awards (reported at $0.00). On 2026-04-06 he exercised/converted 196,513 derivative shares at $0.00. To satisfy tax withholding obligations tied to vested RSUs, 95,014 shares were withheld/disposed on 2026-04-06 at $0.91 per share for a reported withholding amount of $86,273.

Key Details

• Transaction dates: Grants on 2026-03-20; exercise/conversion and tax withholding on 2026-04-06; Form 4 filed 2026-04-08.
• Reported prices/values: Grants and exercise/conversion at $0.00; tax-withheld shares recorded at $0.91/share for $86,273.
• Shares owned after transaction: Not specified in the provided filing details.
• Notable footnotes:
  • RSUs vest over four years with 1/16 vesting on May 20, 2026 and remaining RSUs vesting in equal quarterly installments thereafter (F1, F4).
  • The withheld 95,014 shares satisfied tax obligations arising from vesting of RSUs granted April 4, 2022 (original grant reported on Form 4 filed April 6, 2022) (F2, F5).
  • The derivative award becomes exercisable as to 1/16 of the underlying shares on May 20, 2026, with remaining vesting in equal quarterly installments thereafter (F3).
• Filing timeliness: Grants dated March 20 were reported on April 8 (appears late relative to the usual two-business-day Form 4 deadline); the April 6 conversion/withholding was reported on April 8 (within two business days).

Context

• This filing reflects awards and standard post-vesting mechanics (conversion/exercise and shares withheld to cover taxes), not an open-market sale or purchase. The conversion/exercise at $0.00 reflects exercising/vesting of previously granted derivative awards/RSUs rather than a cash purchase. Withheld shares to cover taxes are routine and do not by themselves indicate a change in the insider’s market view.